Daniel A. Filippa

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz et al. · Blood · 2001 · 427 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer et al. · Blood · 2004 · 406 citations · Full text

Medicine, Immunology, Pharmacotherapy +12

Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma

Kenneth Offit, Francesco Lo‐Coco, Diane C. Louie et al. · New England Journal of Medicine · 1994 · 378 citations · Full text

Medicine, Hematology, Oncology +14

Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

Craig H. Moskowitz, Heiko Schöder, Julie Teruya‐Feldstein et al. · Journal of Clinical Oncology · 2010 · 326 citations · Full text

Medicine, Oncology, Radiology +14

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

Craig H. Moskowitz, Joseph R. Bertino, Jill R. Glassman et al. · Journal of Clinical Oncology · 1999 · 303 citations

Medicine, Hematology, Oncology +14